Home/Filings/4/0001479290-18-000091
4//SEC Filing

Browne L Daniel 4

Accession 0001479290-18-000091

CIK 0001479290other

Filed

Jul 2, 8:00 PM ET

Accepted

Jul 3, 8:17 PM ET

Size

5.8 KB

Accession

0001479290-18-000091

Insider Transaction Report

Form 4
Period: 2018-06-29
Browne L Daniel
DirectorCEO and President
Transactions
  • Other

    Common Stock

    2018-06-29$23.33/sh+668$15,586142,543 total
Holdings
  • Common Stock

    (indirect: See footnote)
    409
Footnotes (2)
  • [F1]These shares were acquired by Mr. Browne under the Issuer's 2014 Employee Stock Purchase Plan (the "Plan") on June 29, 2018 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Mr. Browne purchased the maximum number of shares allowable under the Issuer's Plan and Internal Revenue Code Section 423(b)(8) for 2018.
  • [F2]These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.

Issuer

Revance Therapeutics, Inc.

CIK 0001479290

Entity typeother

Related Parties

1
  • filerCIK 0001597583

Filing Metadata

Form type
4
Filed
Jul 2, 8:00 PM ET
Accepted
Jul 3, 8:17 PM ET
Size
5.8 KB